<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>315068</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>7679709</PubmedId>
            <Abstract>We have recently developed the technology to identify and characterize the human histocompatibility leukocyte antigen (HLA) class I-restricted, CD8+ cytotoxic T lymphocyte (CTL) response to hepatitis B virus (HBV)-encoded antigens in patients with acute viral hepatitis. CTL are expanded in vitro by stimulation with HBV-derived synthetic peptides and selected by restimulation with a panel of HLA-matched stable transfectants that express the corresponding HBV protein. We have recently reported the existence of an HLA-A2-restricted, CD8+ CTL response to an epitope located between residues 18 and 27 of the HBV nucleocapsid core antigen (HBcAg). We now report the discovery of a CTL epitope located between HBcAg residues 141 and 151 that completely overlaps a critical domain in the viral nucleocapsid protein that is essential for its nuclear localization and genome packaging functions as well as processing of the precore protein. The CTL response to this epitope is dually restricted by the HLA-A31 and HLA-Aw68 alleles, which, unexpectedly, appear to use a common binding motif based on the results of alanine substitution and competition analysis, and the binding properties of these two alleles predicted from their known primary sequence, and from the three-dimensional structure of HLA-Aw68. We have also demonstrated that the HBV-specific CTL response to this epitope is polyclonal during acute viral hepatitis, since these two restriction elements can present the HBcAg 141-151 epitope to independent CTL clones derived from a single patient; and that the CTL response is multispecific, since HLA-A2-restricted and HLA-Aw68-restricted CTL responses to HBcAg 18-27 and HBcAg 141-151, respectively, have been identified to coexist in another patient. The foregoing argue against the emergence of CTL escape mutants as a significant problem during HBV infection, especially at this locus, where mutations might be incompatible with viral replication. Finally, our data suggest an association between the HBV-specific CTL response and viral clearance, and they have implications for the design of immunotherapeutic strategies to terminate HBV infection in chronically infected patients.</Abstract>
            <ArticleYear>1993</ArticleYear>
            <ArticlePages>751-62</ArticlePages>
            <ArticleTitle>HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Missale</LastName>
                    <ForeName>G</ForeName>
                </Author>
                <Author>
                    <LastName>Redeker</LastName>
                    <ForeName>A</ForeName>
                </Author>
                <Author>
                    <LastName>Person</LastName>
                    <ForeName>J</ForeName>
                </Author>
                <Author>
                    <LastName>Fowler</LastName>
                    <ForeName>P</ForeName>
                </Author>
                <Author>
                    <LastName>Guilhot</LastName>
                    <ForeName>S</ForeName>
                </Author>
                <Author>
                    <LastName>Schlicht</LastName>
                    <ForeName>H J</ForeName>
                </Author>
                <Author>
                    <LastName>Ferrari</LastName>
                    <ForeName>C</ForeName>
                </Author>
                <Author>
                    <LastName>Chisari</LastName>
                    <ForeName>F V</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.</Affiliations>
            <ArticleChemicalList>Epitopes;HLA-A Antigens;HLA-A*68 antigen;HLA-A31 antigen;Hepatitis B Antigens;Hepatitis B Core Antigens;Viral Core Proteins</ArticleChemicalList>
            <ArticleMeshHeadingsList>Acute Disease; Alleles; Amino Acid Sequence; Capsid(immunology); Cell Line; Epitopes(immunology); Female; HLA-A Antigens(analysis; genetics); Hepatitis B(immunology); Hepatitis B Antigens(immunology; pharmacology); Hepatitis B Core Antigens(analysis; immunology; pharmacology); Hepatitis B virus(immunology); Humans; Male; Molecular Sequence Data; T-Lymphocytes, Cytotoxic(immunology; pathology); Transfection; Viral Core Proteins(immunology)</ArticleMeshHeadingsList>
            <Comments>Data originally imported from the Database of Functional Molecular Immunology, FIMM (http://sdmc.lit.org.sg:8080/fimm/) and from the HLA Ligand Database (http://hlaligand.ouhsc.edu/)</Comments>
            <Journal>
                <Volume>177</Volume>
                <Issue>3</Issue>
                <Title>The Journal of experimental medicine</Title>
                <Issn>0022-1007</Issn>
                <MedlineTa>J Exp Med</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>STLPETTVVRR</LinearSequence>
                        <StartingPosition>141</StartingPosition>
                        <EndingPosition>151</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P17392.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10415</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <EpitopeId>61745</EpitopeId>
                <ReferenceStartingPosition>141</ReferenceStartingPosition>
                <ReferenceEndingPosition>151</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The following refers to the epitope id as found in the original FIMM database: P000219, P000256.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 5 and 6</LocationOfData>
                        <TCellId>1355482</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>STLPETTVVRR</LinearSequence>
                                            <StartingPosition>141</StartingPosition>
                                            <EndingPosition>151</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P17392.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10415</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>CTL lines were established from two patients where autologous PMBC were initially cultured with HBcAg peptide 140-155 plus rHBcAg followed by weekly restimulation with peptide 140-155 and rIL-2. CTL clones were generated by limiting dilution (one cell per well in 96-well plate) from one of the aforementioned HBcAg 140-155-specific cell lines and restimulated with 10^5 irradiated autologous B-LCL transfectants expressing the  HBV core region, with 2 x 10^6 allogeneic irradiated PBMC feeder cells per well.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>249</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Core antigen</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P17392.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10415</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <RecombinantOrganism>
                                    <SubType>Recombinant Organism</SubType>
                                    <RecombinantOrganismId>10245</RecombinantOrganismId>
                                </RecombinantOrganism>
                            </AntigenContainingObject>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Two CTL lines (E4 and H1) and two CTL clones (2D7 and 3D11) lysed target cells (B-LCL), infected with recombinant vaccinia virus that expressed the HBV core protein, via recognition of the epitope from endogenously synthesized HBcAg.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 2, 4, 7, 8, 9 and Tables 2, 3</LocationOfData>
                        <TCellId>315321</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>STLPETTVVRR</LinearSequence>
                                            <StartingPosition>141</StartingPosition>
                                            <EndingPosition>151</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P17392.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10415</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>CTL lines were established from two patients where autologous PMBC were initially cultured with HBcAg peptide 140-155 plus rHBcAg followed by weekly restimulation with peptide 140-155 and rIL-2. CTL clones were generated by limiting dilution (one cell per well in 96-well plate) from one of the aforementioned HBcAg 140-155-specific cell lines and restimulated with 10^5 irradiated autologous B-LCL transfectants expressing the  HBV core region, with 2 x 10^6 allogeneic irradiated PBMC feeder cells per well.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>245</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBcAg141-151</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>STLPETTVVRR</LinearSequence>
                                        <StartingPosition>141</StartingPosition>
                                        <EndingPosition>151</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P17392.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10415</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The 11-mer, HBcAg 141-151, was found to be the minimal optimal epitope via truncation analysis using HBcAg 140-155-specific T cell clones. Additionally, critical residues of the epitope were identified that interacted with the HLA-A31 molecule or with the T cell receptor from clone 3D11. Through alanine substitution, E145 and V149 were demonstrated to be TCR-binding residues, and L143, R150, and R151 were shown to be MHC-binding residues.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 2, 3, 4, 7, 8, 9 and Tables 2, 3</LocationOfData>
                        <TCellId>1355478</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>STLPETTVVRR</LinearSequence>
                                            <StartingPosition>141</StartingPosition>
                                            <EndingPosition>151</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P17392.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10415</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>CTL lines were established from two patients where autologous PMBC were initially cultured with HBcAg peptide 140-155 plus rHBcAg followed by weekly restimulation with peptide 140-155 and rIL-2. CTL clones were generated by limiting dilution (one cell per well in 96-well plate) from one of the aforementioned HBcAg 140-155-specific cell lines and restimulated with 10^5 irradiated autologous B-LCL transfectants expressing the  HBV core region, with 2 x 10^6 allogeneic irradiated PBMC feeder cells per well.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>249</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HBcAg141-151</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>STLPETTVVRR</LinearSequence>
                                        <StartingPosition>141</StartingPosition>
                                        <EndingPosition>151</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P17392.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10415</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The 11-mer, HBcAg 141-151, was found to be the minimal optimal epitope via truncation analysis using HBcAg 140-155-specific T cell clones. Additionally, critical residues of the epitope were identified that interacted with the HLA-Aw68 molecule or with the T cell receptor from clone 2D7. Through alanine substitution, T146 and T147 were demonstrated to be TCR-binding residues, and L143 and R151 were shown to be MHC-binding residues.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 5 and 6</LocationOfData>
                        <TCellId>1355479</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2043</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis B virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>STLPETTVVRR</LinearSequence>
                                            <StartingPosition>141</StartingPosition>
                                            <EndingPosition>151</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P17392.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10415</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>CTL lines were established from two patients where autologous PMBC were initially cultured with HBcAg peptide 140-155 plus rHBcAg followed by weekly restimulation with peptide 140-155 and rIL-2. CTL clones were generated by limiting dilution (one cell per well in 96-well plate) from one of the aforementioned HBcAg 140-155-specific cell lines and restimulated with 10^5 irradiated autologous B-LCL transfectants expressing the  HBV core region, with 2 x 10^6 allogeneic irradiated PBMC feeder cells per well.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (EBV transformed, B-LCL)</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>245</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Core antigen</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P17392.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10415</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <RecombinantOrganism>
                                    <SubType>Recombinant Organism</SubType>
                                    <RecombinantOrganismId>10245</RecombinantOrganismId>
                                </RecombinantOrganism>
                            </AntigenContainingObject>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Two CTL lines (E4 and H1) and two CTL clones (2D7 and 3D11) lysed target cells (B-LCL), infected with recombinant vaccinia virus that expressed the HBV core protein, via recognition of the epitope from endogenously synthesized HBcAg.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HBcAg141-151 Analog L143A</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>STAPETTVVRR</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 9</LocationOfData>
                <EpitopeId>61526</EpitopeId>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Analog of natural epitope with alanine substitution at residue L143.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 9</LocationOfData>
                        <MhcBindingId>1355759</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>226</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Peptide containing an alanine substitution at residue L143 did not compete with the natural epitope, HBcAg141-151, for binding to HLA-Aw68, suggesting that L143 is likely involved in the interaction of HBcAg141-151 with HLA-Aw68.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>249</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 9</LocationOfData>
                        <MhcBindingId>1355758</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>226</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Peptide containing an alanine substitution at residue L143 did not compete with the natural epitope, HBcAg141-151, for binding to HLA-A31, suggesting that L143 is likely involved in the interaction of HBcAg141-151 with HLA-A31.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>245</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HBcAg141-151 Analog E145A</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>STLPATTVVRR</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 9</LocationOfData>
                <EpitopeId>61735</EpitopeId>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Analog of natural epitope with alanine substitution at residue E145.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 9</LocationOfData>
                        <MhcBindingId>1355765</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>226</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Peptide containing an alanine substitution at residue E145 did compete with the natural epitope, HBcAg141-151, for binding to HLA-A31, suggesting that E145 is not likely involved in the interaction of HBcAg141-151 with HLA-A31.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>245</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HBcAg141-151 Analog T146A</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>STLPEATVVRR</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 9</LocationOfData>
                <EpitopeId>61737</EpitopeId>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Analog of natural epitope with alanine substitution at residue T146.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 9</LocationOfData>
                        <MhcBindingId>1355777</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>226</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Peptide containing an alanine substitution at residue T146 did compete with the natural epitope, HBcAg141-151, for binding to HLA-Aw68, suggesting that T146 is not likely involved in the interaction of HBcAg141-151 with HLA-Aw68.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>249</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HBcAg141-151 Analog T147A</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>STLPETAVVRR</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 9</LocationOfData>
                <EpitopeId>61739</EpitopeId>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Analog of natural epitope with alanine substitution at residue T147.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 9</LocationOfData>
                        <MhcBindingId>1355782</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>226</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Peptide containing an alanine substitution at residue T147 did compete with the natural epitope, HBcAg141-151, for binding to HLA-Aw68, suggesting that T147 is not likely involved in the interaction of HBcAg141-151 with HLA-Aw68.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>249</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HBcAg141-151 Analog V149A</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>STLPETTVARR</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 9</LocationOfData>
                <EpitopeId>61740</EpitopeId>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Analog of natural epitope with alanine substitution at residue V149.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 9</LocationOfData>
                        <MhcBindingId>1355783</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>226</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Peptide containing an alanine substitution at residue V149 did compete with the natural epitope, HBcAg141-151, for binding to HLA-A31, suggesting that V149 is not likely involved in the interaction of HBcAg141-151 with HLA-A31.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>245</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HBcAg141-151 Analog R150A</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>STLPETTVVAR</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 9</LocationOfData>
                <EpitopeId>61742</EpitopeId>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Analog of natural epitope with alanine substitution at residue R150.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 9</LocationOfData>
                        <MhcBindingId>1355785</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>226</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Peptide containing an alanine substitution at residue R150 did not compete with the natural epitope, HBcAg141-151, for binding to HLA-A31, suggesting that R150 is likely involved in the interaction of HBcAg141-151 with HLA-A31.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>245</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HBcAg141-151 Analog R151A</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>STLPETTVVRA</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Figure 9</LocationOfData>
                <EpitopeId>61744</EpitopeId>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Analog of natural epitope with alanine substitution at residue R151.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 9</LocationOfData>
                        <MhcBindingId>1355787</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>226</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Peptide containing an alanine substitution at residue R151 did not compete with the natural epitope, HBcAg141-151, for binding to HLA-Aw68, suggesting that R151 is likely involved in the interaction of HBcAg141-151 with HLA-Aw68.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>249</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 9</LocationOfData>
                        <MhcBindingId>1355788</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>226</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Peptide containing an alanine substitution at residue R151 did not compete with the natural epitope, HBcAg141-151, for binding to HLA-A31, suggesting that R151 is likely involved in the interaction of HBcAg141-151 with HLA-A31.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>245</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

